Novartis
Novartis follows Pfizer’s lead, pledges no price hikes in 2018
July 18, 2018Research and Development, Sales and Marketing Novartis, Pfizer, President trump, Trump, US, pharma
Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the …
Senate claims Novartis misled public on Trump lawyer deal
July 16, 2018Sales and Marketing Novartis, Senate, Trump, United States, deal
A report released by the United States Senate has found that Novartis’ relationship with Donald Trump’s long-time lawyer Michael Cohen …
Novartis pulls out of antibiotics, cuts 140 staff
July 12, 2018Sales and Marketing Antibiotics, Novartis, pharma, staff cuts
Novartis has announced that it is to terminate its research operations into antibiotics and antivirals in a reorganisation effort that …
CHMP recommends Novartis’ CAR-T therapy Kymriah for EU approval
July 5, 2018Sales and Marketing CAR-T, CHMP, EMA, EU, Kymriah, Novartis, pharma
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) approve Novartis’ CAR-T …
Novartis secures US rights to Adamis’ epinephrine auto injector
July 3, 2018Manufacturing and Production, Sales and Marketing Adamis, Novartis, Symjepi, US, auto injector, pharma
Novartis has penned an agreement with Adamis Pharmaceuticals to commercialise and distribute the latter’s epinephrine auto injector Symjepi in the …
Novartis spins off Alcon as CEO focuses drug search
June 29, 2018Medical Communications, Sales and Marketing Alcon, Novartis, eye care, pharma
Novartis has announced a plan to spinoff Alcon – its eye care division – into a separately-traded standalone company.Novartis has …
Novartis’ US Oncology head makes leap to become biotech CEO
June 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis
The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill …
Amgen/Novartis migraine med gets CHMP nod
June 4, 2018Sales and Marketing Aimovig, Amgen, Novartis, biotech, drugs, pharma, pharmaceutical
Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …
Novartis’ US Oncology head makes leap to become biotech CEO
June 1, 2018Medical Communications Novartis, axcella, biotech, drugs, pharma, pharmaceutical
The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill …
Top Ten most popular articles on Pharmafile.com this week
May 25, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cancer, Gielad, Novartis, brexit, obesity, pharma, top ten
It’s a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an …
Novartis’ Sandoz scores EU approval for Remicade biosimilar
May 24, 2018Sales and Marketing EU, Europe, Novartis, Remicade, Sandoz, Zessly, pharma
The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s …
Investigation of kickbacks in Greece sputters to halt
May 21, 2018Sales and Marketing Greece, Novartis, biotech, drugs, pharma, pharmaceutical
Greek parliament has decided against investigating allegations of bribery, involving Novartis and numerous high-level former politicians. The case has dominated …
Top Ten most popular articles on Pharmafile.com this week
May 18, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, Novartis, Takeda, Trump, brexit, pharma, pharmafile, top ten
The year is flying by – it’s another Friday, and that means another Top Ten run-down.Perhaps the biggest story this …
Amgen/Novartis potential blockbuster migraine med gets FDA nod
May 18, 2018Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical
The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …
Novartis’ top lawyer retires from role over botched Trump deal
May 16, 2018Medical Communications, Research and Development Michael Cohen, Novartis, Trump, pharma
The saga of Novartis’ ill-advised $1.2 million deal with US President Donald Trump’s lawyer Michael Cohen continues to unfold as …
Latest content
FibroFind appoints Lee Borthwick as CEO
